Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Slideshows|May 14, 2026
2026 AAN Annual Meeting: Top Interviews and Expert Perspectives
Author(s)Louie Pasculli
Fact checked by: Marco Meglio
Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.
Advertisement
Advertisement
The 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22, in Chicago, Illinois, brought together thousands of clinicians, researchers, trainees, and industry leaders for one of the field’s premier neurology conferences. This year’s meeting featured plenary sessions focused on ongoing controversies in neurology, presentations highlighting advances in translational science, late-breaking clinical data, award lectures, and discussions spanning nearly every subspecialty in neurology.
Related to this article
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.
Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins.
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.
Advertisement
Advertisement